Mounjaro and General Anaesthetic: What to Tell Your Surgical Team

Why does Mounjaro affect how general anaesthesia works?

The core issue is gastric emptying. Tirzepatide (the active medicine in Mounjaro) acts on both GIP and GLP-1 receptors in the gut, and one of its effects is slowing the rate at which the stomach moves its contents into the small intestine. This is part of how it reduces appetite and blood-sugar spikes. During normal daily life, that slowing is a benefit. In the context of a general anaesthetic, it becomes a clinical concern.

Anaesthesia relaxes the muscles that protect the airway. If the stomach still contains food or liquid at the point of induction, there is a risk of regurgitation and aspiration (stomach contents entering the lungs) which can cause serious harm. Standard pre-operative fasting guidance (typically six hours for food, two hours for clear fluids) is designed around a stomach that empties at the usual rate. Because tirzepatide can extend that window, the usual fasting period may not be sufficient to guarantee an empty stomach. Anaesthetists need to know this so they can adapt their approach, which might include extending the fasting period, choosing a specific type of airway management, or recommending a precautionary pause to treatment before surgery.

NHS England's guidance on weight-management injections specifically advises patients to inform their healthcare team, including the anaesthetist, before any surgical procedure. This is consistent with the advice in the NHS England weight-management injections guidance.

Should you stop Mounjaro before having a general anaesthetic?

This is the question most people ask, and the honest answer is: it depends, and it is not a decision to make without guidance. Some surgical teams do ask patients to stop Mounjaro for a period before an elective procedure. Others manage the risk through adjusted fasting protocols and airway technique without requiring a pause. There is no single rule because the right approach varies with the type of surgery, whether it is elective or emergency, the dose of Mounjaro you are taking, and your wider clinical picture.

What is consistent in UK guidance is the obligation to disclose. The NHS medicines page for tirzepatide advises patients to tell any healthcare professional treating them that they are taking the medicine. That conversation should happen early, well before your admission date, so your team has time to plan.

If you are considering your treatment options or want to discuss how Mounjaro fits around a planned procedure, you can check your eligibility through a free consultation, where a GPhC-registered prescriber can review your full picture. On general questions about tirzepatide as a medicine, our tirzepatide overview covers the clinical background.

What does this mean in practice before your operation?

Most people reading this want a concrete checklist rather than a general principle. Here is what the guidance points to.

First, flag it early. As soon as you have a surgery date, contact whoever is managing your Mounjaro treatment and the pre-operative assessment team at the hospital. Do not wait for the assessment call to mention it; note it on any pre-admission questionnaire too. A quick check of your pre-admission paperwork right now, to see whether there is a medicines section you have not completed, takes under a minute and could prevent a same-day cancellation.

Second, do not adjust your dose or pause treatment without being told to. Some patients stop Mounjaro the week before surgery out of caution, without informing their prescriber. This is not advisable: your prescriber needs to know about any interruption so your titration plan remains accurate and your records are current.

Third, ask specifically about restarting. After surgery, nausea is common, and GI side effects from tirzepatide may compound post-operative recovery if you restart too quickly. Your clinical team should advise on timing. If you have questions about the medicine itself, the Mounjaro treatment page covers the licensed indications and how the clinical process works at nume.

Emergency surgery is a separate situation. There will not be time for a pre-operative adjustment, which is why your medical records and any emergency contacts should reflect that you take this medicine. A medical alert note (in your phone, wallet, or a regular medicines list shared with a trusted person) is worth having.

Does this only apply to Mounjaro, or to GLP-1 medicines in general?

The gastric-emptying concern applies across the GLP-1 class. Semaglutide (the active ingredient in Wegovy) works through the GLP-1 receptor alone and also slows gastric emptying, raising similar considerations before general anaesthesia. The degree of slowing may differ between medicines and doses, and the clinical evidence specific to each is still developing. What is consistent is that any GLP-1 or dual-agonist medicine should be disclosed to your anaesthetist ahead of any procedure, and if you want a deeper look at how tirzepatide is known by different names across its licensed uses, our page on Mounjaro generic names explains the terminology clearly.

Professional anaesthetic bodies in the UK have been updating their guidance on GLP-1 medicines and surgery as evidence accumulates, and your surgical team will be familiar with the issue. The concern is not a reason to avoid Mounjaro as a treatment, it is a reason to communicate clearly. If you want to understand how Mounjaro compares with other licensed weight-loss medicines before making a decision, our page on Mounjaro and anaesthesia considerations goes further on the clinical detail, and the weight loss treatment overview explains the broader options. For questions about our clinical team's approach to safety, our lead prescriber's profile is worth a read, and you can also hear prescribers discuss surgical considerations and patient safety in our Mounjaro podcast, which covers topics like Mounjaro and general anesthesia in plain, accessible terms.